The CDV Laboratory, after its successful operation with Indonesia, where it exported 6,000,000 total doses of foot-and-mouth disease vaccines in 2022, opened new markets, this time in the Southern Cone region.
The company was selected by Uruguay as a qualified supplier for the shipment of 1 million doses of foot-and-mouth disease vaccines, within the framework of a campaign that includes 16 million doses that will be applied in two stages during 2023.
CDV became a supplier to Uruguay after having participated in an International Public Tender called by the Ministry of Livestock, Agriculture and Fisheries (MGAP) of that country, together with eight laboratories.
Uruguay, like Argentina, are countries where clinical surveillance does not detect the presence of the disease and serological studies show the absence of viral circulation in their territories, a condition that recognizes them with the status “free of foot-and-mouth disease with vaccination” before the World Organization for Animal Health (OIE). To maintain the status, tests are carried out every year to demonstrate the absence of the disease, with preventive vaccination campaigns being key to maintaining the sanitary status and controlling the disease.
CDV, which has a plant dedicated to the exclusive manufacture of foot-and-mouth disease vaccines, authorized by SENASA in 2017, with a production capacity of more than 40 million doses of mono, bi, tri and tetravalent vaccine per year, “deepens its fight for the preservation of animal health, not only locally but also in the South American region”, the company indicated.
In this sense, he reported that “in the coming years it will continue its development and growth with the construction of a third vaccine manufacturing plant in the Pilar Industrial Park, with an area of 11,000 m2 and which will be operational in the first quarter of 2025, its capacity will increase to a total of 280 million doses, of which 190 million correspond to vaccines for bovines to prevent the main diseases that affect production (destined for the domestic market and for export) and the rest correspond to vaccines for salmonids”.
